Haloperidol and QT prolongation and Torsades de Pointes
admin September 18th, 2007
Johnson and Johnson and the FDA have informed healthcare professionals of the risks of sudden death, QT prolongation and Torsades de Pointes(TdP) in patients treated with haloperidol, especially when given intravenously, or at doses higher than recommended. They report:
There are at least 28 case reports of QT prolongation and TdP, some with fatal outcome in the context of off-label intravenous haloperidol. Healthcare professionals should consider this new risk information when making individual treatment decisions for their patients.